Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

ClinicalTrials.gov ID: NCT00668031

Public ClinicalTrials.gov record NCT00668031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery

Study identification

NCT ID: NCT00668031
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 359 participants

Conditions and interventions

Conditions

Blood Loss, Surgical

Interventions

Trasylol (Aprotinin, BAYA0128) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2005
Primary completion: Dec 31, 2005
Completion: Dec 31, 2005
Last update posted: Dec 29, 2014

2005 – 2006

United States locations

U.S. sites: 27
U.S. states: 16
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Mobile	Alabama	36608	—
Not listed	Phoenix	Arizona	85023	—
Not listed	La Jolla	California	92037	—
Not listed	San Diego	California	92123	—
Not listed	Aurora	Colorado	80012	—
Not listed	Farmington	Connecticut	06032	—
Not listed	Bay Pines	Florida	33744	—
Not listed	Jacksonville Beach	Florida	32250	—
Not listed	Sarasota	Florida	34239	—
Not listed	St. Petersburg	Florida	33703	—
Not listed	Boise	Idaho	83702	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Mooresville	Indiana	46158	—
Not listed	Iowa City	Iowa	52242-1089	—
Not listed	Baltimore	Maryland	21215	—
Not listed	Worcester	Massachusetts	01655	—
Not listed	Kalamazoo	Michigan	49009	—
Not listed	Ypsilanti	Michigan	48197	—
Not listed	Durham	North Carolina	27710	—
Not listed	Greensboro	North Carolina	27401	—
Not listed	Bend	Oregon	97701	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Pittsburgh	Pennsylvania	15213-2592	—
Not listed	Dallas	Texas	75231	—
Not listed	Lubbock	Texas	79410	—
Not listed	San Antonio	Texas	78233	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00668031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 29, 2014 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00668031 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →